FP-208 is under clinical development by Beijing Foreland Pharma and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FP-208’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FP-208 is under development for the treatment of solid tumours including kidney cancer, breast cancer, neuroendocrine tumor, sarcoma, liver cancer and ovarian cancer as second line therapy. The drug candidate is an imidazolone derivative administered through oral and intravenous routes. It acts by targeting serine/threonine-protein kinase mTOR.
For a complete picture of FP-208’s drug-specific PTSR and LoA scores, buy the report here.